Sign inJoin waitlistJoin the waitlist

JP

Joseph Pennington

Physician · Virginia Urology Center

Credentials: · · · ·

History

Virginia Urology Center
Present

Radiation Oncology
UCLA David Geffen School of Medicine/UCLA Medical Center
2016–2017
Diagnostic Radiology
Vanderbilt University Medical Center
2012–2016
General Surgery
Vanderbilt University Medical Center
2008–2013
Vanderbilt University School of Medicine
2008–2012

Research

Sirt3-mediated deacetylation of evolutionarily conserved lysine 122 regulates MnSOD activity in response to stress
Molecular Cell · 2010 · 756 citations
SIRT3 is a mitochondria-localized tumor suppressor required for maintenance of mitochondrial integrity and metabolism during stress
Cancer Cell · 2010 · 667 citations
SIRT3 interacts with the daf-16 homolog FOXO3a in the mitochondria, as well as increases FOXO3a dependent gene expression
International Journal of Biological Sciences · 2008 · 250 citations

David Gius
8 papers
Mark Mishra
3 papers
Percy Lee
3 papers
David Demanes
2 papers
Hyunseok Kim
2 papers
Mitchell Kamrava
2 papers · 1 as a fellow
Tony Wang
2 papers
Amar Kishan
1 paper
Anji Wall
1 paper · 1 as a resident
Anusha Kalbasi
1 paper
Aradhana Kaushal
1 paper
Arun Singh
1 paper

Grants

NCI Community Oncology Research Program (NCORP) Community Sites (UG1 Clinical Trial Required)
National Cancer Institute · UG1
PI · $13.9M · Southeast Clinical Oncol Res Consortium
2014–2027
Intramitochondrial Function of the Deacetylase SIRT3
National Institute on Aging · F30
Contact PI · $102.6K · Vanderbilt University
2009–2012

Clinical trials

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study
Site PI · Recruiting · Phase 3
NRG Oncology
2025–2035
Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2025–2032
Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
Site PI · Recruiting · Phase 3
Canadian Cancer Trials Group
2025–2031
Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer
Site PI · Recruiting · Phase 3
Alliance for Clinical Trials in Oncology
2025–2037